{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:37:55Z","timestamp":1776134275872,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006668","name":"Oregon Health & Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CytoDyn"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In an exploratory trial treating \u201clong COVID\u201d with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab.<\/jats:p>\n               <jats:p>Clinical Trials Registration. NCT04678830.<\/jats:p>","DOI":"10.1093\/cid\/ciac226","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:18:09Z","timestamp":1649935089000},"page":"1232-1234","source":"Crossref","is-referenced-by-count":24,"title":["Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome"],"prefix":"10.1093","volume":"75","author":[{"given":"Norman B","family":"Gaylis","sequence":"first","affiliation":[{"name":"Arthritis & Rheumatic Disease Specialties , Aventura, Florida , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Ritter","sequence":"additional","affiliation":[{"name":"Center for Advanced Research & Education , Gainesville, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A","family":"Kelly","sequence":"additional","affiliation":[{"name":"CytoDyn , Vancouver, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader Z","family":"Pourhassan","sequence":"additional","affiliation":[{"name":"CytoDyn , Vancouver, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenakshi","family":"Tiwary","sequence":"additional","affiliation":[{"name":"Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University , Beaverton, Oregon , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonah B","family":"Sacha","sequence":"additional","affiliation":[{"name":"Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University , Beaverton, Oregon , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott G","family":"Hansen","sequence":"additional","affiliation":[{"name":"Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University , Beaverton, Oregon , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Recknor","sequence":"additional","affiliation":[{"name":"CytoDyn , Vancouver, Washington , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto O","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California\u2013Los Angeles , Los Angeles, California , USA"},{"name":"Department of Microbiology, Immunology, and Molecular Genetics, University of California\u2014Los Angeles , Los Angeles, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"2022093020234493900_CIT0001","doi-asserted-by":"crossref","first-page":"101019","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.","volume":"38","author":"Davis","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022093020234493900_CIT0002","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3389\/fimmu.2017.01981","article-title":"The expanding therapeutic perspective of CCR5 blockade.","volume":"8","author":"Vangelista","year":"2017","journal-title":"Front Immunol"},{"key":"2022093020234493900_CIT0003","doi-asserted-by":"crossref","first-page":"738687","DOI":"10.3389\/fmed.2021.738687","article-title":"Unraveling risk genes of COVID-19 by multi-omics integrative analyses.","volume":"8","author":"Baranova","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2022093020234493900_CIT0004","article-title":"Regulatory noncoding and predicted pathogenic coding variants of CCR5 predispose to severe COVID-19.","volume":"22:5372","author":"Cantalupo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2022093020234493900_CIT0005","doi-asserted-by":"crossref","first-page":"107825","DOI":"10.1016\/j.intimp.2021.107825","article-title":"Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity.","volume":"98","author":"Cuesta-Llavona","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2022093020234493900_CIT0006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection.","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin Trials"},{"key":"2022093020234493900_CIT0007","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022093020234493900_CIT0008","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1086\/592169","article-title":"Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.","volume":"198","author":"Jacobson","year":"2008","journal-title":"J Infect Dis"},{"key":"2022093020234493900_CIT0009","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.","volume":"201","author":"Jacobson","year":"2010","journal-title":"J Infect Dis"},{"key":"2022093020234493900_CIT0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","article-title":"CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.","volume":"103","author":"Patterson","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2022093020234493900_CIT0011","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/JVI.73.5.4145-4155.1999","article-title":"Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.","volume":"73","author":"Olson","year":"1999","journal-title":"J Virol"},{"key":"2022093020234493900_CIT0012","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1038\/s41467-021-23697-6","article-title":"Antibody-based CCR5 blockade protects macaques from mucosal SHIV transmission.","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"2022093020234493900_CIT0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.794638","article-title":"CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody leronlimab","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"2022093020234493900_CIT0014","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1093\/emboj\/20.10.2497","article-title":"Chemokine receptor homo- or heterodimerization activates distinct signaling pathways","volume":"20","author":"Mellado","year":"2001","journal-title":"EMBO J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac226\/43408463\/ciac226.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/7\/1232\/46227312\/ciac226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/7\/1232\/46227312\/ciac226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T20:30:24Z","timestamp":1664569824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/7\/1232\/6572226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,22]]},"published-print":{"date-parts":[[2022,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac226","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,4,22]]}}}